| Code | CSB-RA004929MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to STI-5171, targeting CD38, a type II transmembrane glycoprotein with both receptor and ectoenzyme functions. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and participates in calcium signaling pathways essential for cellular activation and proliferation. This protein is highly expressed on various immune cells, including plasma cells, activated T cells, and natural killer cells. CD38 has emerged as a critical marker in hematological malignancies, particularly multiple myeloma, where it shows significant overexpression on malignant plasma cells, making it an important therapeutic target and diagnostic marker.
STI-5171 is a well-characterized anti-CD38 antibody that has been utilized extensively in immunology and oncology research. This biosimilar provides researchers with a reliable tool for investigating CD38-mediated signaling mechanisms, studying immune cell function, and exploring therapeutic strategies in hematological disorders. The antibody is suitable for various research applications examining CD38 expression patterns, cellular interactions, and functional roles in both normal physiology and disease states.
There are currently no reviews for this product.